Latest Stock Market News

On the second day of bidding, the retail portion of the issue was subscribed 79%, while the non-institutional investors category saw a 98% subscription. Meanwhile, qualified institutional buyers subscribed to 54% of their allotted portion.

Long unwinding is the sale of long-held stocks or positions to book profits or exit ahead of an expected downturn.

Bitcoin is more than just digital gold—the Jaipur edition of Crypto Ki Paathshala uncovered many more such interesting insights on trends, regulatory nuances, portfolio diversification, and the evolving crypto landscape in India. Experts explored critical aspects of cryptocurrency, shedding light on its adoption and future potential.

In the last 24 hours, Bitcoin s market cap fell to $1.907 trillion, with its dominance now at 59.91%. BTC s trading volume during this period rose by 20% to $18.19 billion. Meanwhile, stablecoins made up $58.31 billion of this volume, or 91.06%, according to CoinMarketCap.

Leading brokerage firms have recommended buying stocks like Vedanta, Bharti Airtel, Hindalco, HCL Technologies, and Ipca Laboratories, forecasting returns of 12-32% over the next 12 months. Citi, CLSA, and Motilal Oswal have highlighted these stocks across sectors with specific target prices, suggesting significant upside potential for investors.

The Nifty Realty index was trading 0.64 per cent down at 826.1.

Zen Technologies shares fell 20% after reporting a sequential decline in profitability and revenue for Q3 FY25. Despite a 22% YoY profit increase, sequential net profit dropped 40.8%. The company’s operational performance weakened, with a 33.18% drop in EBITDA. Despite recent setbacks, analyst sentiment remains bullish with a target price of Rs 2,495.

The Nifty 50 shows signs of recovery after a 7-day decline, with an 88% historical chance of a rebound, as reported by Samco Securities. Over 12 years, each seven-day losing streak led to a 1.6% gain on average the following week.

Godfrey Phillips share price: The company reported a significant 27.2% year-on-year (YoY) increase in its net profit, along with a 14.8% rise in its revenue from operations for Q3 FY25.

US tariffs on pharmaceutical imports will affect India’s pharma sector, a leader in affordable generics. Analyst Vishal Manchanda highlights risks to Indian firms like Sun Pharma and Cipla due to pricing pressures, but anticipates growth in domestic and emerging markets.